Literature DB >> 12126865

24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder.

Anita C Volkers1, Joke H M Tulen, Walter W Van Den Broek, Jan A Bruijn, Jan Passchier, Lolke Pepplinkhuizen.   

Abstract

Psychomotor dysfunction in depression is related to alterations in the 24-h pattern of motor activity. After antidepressant treatment the diurnal pattern may be changed due to improvement of clinical state or pharmacological actions. The purpose of this study was to evaluate in 52 depressed in-patients the effects of imipramine (tricyclic antidepressant) and fluvoxamine (SSRI) on the 24-h motor activity. Motor activity was monitored by wrist-actigraphy during a medication-free period and after 4 weeks of treatment. Clinical improvement was not different after imipramine or fluvoxamine treatment. The Hamilton depression score decreased in patients treated with imipramine, as well as in patients treated with fluvoxamine. The clinical retardation score was also reduced in both treatment groups. However, patients treated with imipramine showed higher motor activity levels during the wake period in comparison to the medication-free period, and more fragmentation of motor activity during sleep. Treatment with fluvoxamine did not result in alterations in the 24-h pattern of motor activity. The improvement of depressive mood and retardation seems to play a minor role in the change of the pattern of motor activity after imipramine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126865     DOI: 10.1016/s0924-977x(02)00019-6

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  12 in total

Review 1.  Fluvoxamine versus other anti-depressive agents for depression.

Authors:  Ichiro M Omori; Norio Watanabe; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Hugh McGuire; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

2.  Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD Expert Meeting.

Authors:  P H Robert; A Konig; S Andrieu; F Bremond; I Chemin; P C Chung; J F Dartigues; B Dubois; G Feutren; R Guillemaud; P A Kenisberg; S Nave; B Vellas; F Verhey; J Yesavage; P Mallea
Journal:  J Nutr Health Aging       Date:  2013       Impact factor: 4.075

3.  Actigraphic registration of motor activity reveals a more structured behavioural pattern in schizophrenia than in major depression.

Authors:  Jan O Berle; Erik R Hauge; Ketil J Oedegaard; Fred Holsten; Ole B Fasmer
Journal:  BMC Res Notes       Date:  2010-05-27

4.  Modeling nonlinear time-dependent treatment effects: an application of the generalized time-varying effect model (TVEM).

Authors:  Mariya P Shiyko; Jack Burkhalter; Runze Li; Bernard J Park
Journal:  J Consult Clin Psychol       Date:  2013-12-23

Review 5.  Bringing the bedside to the bench, and then to the community: a prospectus for intervention research in late-life anxiety disorders.

Authors:  Eric J Lenze; Julie Loebach Wetherell
Journal:  Int J Geriatr Psychiatry       Date:  2009-01       Impact factor: 3.485

Review 6.  A lifespan view of anxiety disorders.

Authors:  Eric J Lenze; Julie Loebach Wetherell
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

7.  Improving motor activity assessment in depression: which sensor placement, analytic strategy and diurnal time frame are most powerful in distinguishing patients from controls and monitoring treatment effects.

Authors:  Markus Reichert; Alexander Lutz; Michael Deuschle; Maria Gilles; Holger Hill; Matthias F Limberger; Ulrich W Ebner-Priemer
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

Review 8.  Psychomotor retardation in depression: a systematic review of diagnostic, pathophysiologic, and therapeutic implications.

Authors:  Djamila Bennabi; Pierre Vandel; Charalambos Papaxanthis; Thierry Pozzo; Emmanuel Haffen
Journal:  Biomed Res Int       Date:  2013-10-30       Impact factor: 3.411

9.  Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders.

Authors:  Renaud David; Emmanuel Mulin; Patrick Mallea; Philippe H Robert
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-26

10.  Cortico-cortical white matter motor pathway microstructure is related to psychomotor retardation in major depressive disorder.

Authors:  Tobias Bracht; Andrea Federspiel; Susanne Schnell; Helge Horn; Oliver Höfle; Roland Wiest; Thomas Dierks; Werner Strik; Thomas J Müller; Sebastian Walther
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.